Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Apr 2, 2015) - Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors.

The Life Sciences Report: Daniel, Sunesis Pharmaceuticals Inc. has been around for more than 15 years. How does the Sunesis of today compare to its pioneering days?

Daniel Swisher: Sunesis was formed in 1998 with an initial focus on new discovery tools for small molecule drugs to address significant unmet needs. Since then, we've become a late-stage development and pre-commercial company focused on oncology, thus leveraging our pioneering tyrosine kinase work. In addition, we acquired worldwide rights for vosaroxin, our lead development product. What has remained constant is our strong focus on high-quality science and innovation.

TLSR: Has your program evolution been a result of changes in managerial interests over the years?

DS: I'd say our evolution has been driven primarily by shifting from a laboratory-focused, early science-based company to an integrated pre-commercial oncology company...

Continue reading this interview with Daniel Swisher: How Sunesis Pharmaceuticals Can Inhibit Cancer While Enhancing Investments

About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE:
Sunesis Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. David Swisher had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of David Swisher and not of The Life Sciences Report or its officers.